Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabien Subtil

Showing results (151-160 of 165) with videos related to

Pageof 17
Sort By:
American Journal of Hematology|December 11, 2020
First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French studyMarie-Charlotte Laude, Laure Lebras, Pierre Sesques, et al.
Blood|November 9, 2020
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trialAnne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, et al.
The Lancet. Haematology|July 21, 2019
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trialAnne-Sophie Michallet, Marie-Sarah Dilhuydy, Fabien Subtil, et al.
JAMA Neurology|August 4, 2025
Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple SclerosisAntoine Gavoille, Fabien Rollot, Romain Casey, et al.
The European Respiratory Journal|March 26, 2026
Prognostic factors in interstitial lung disease-associated pulmonary hypertension: data from the HYPID cohort and the French Pulmonary Hypertension RegistryRémi Diesler, Ségolène Turquier, Martine Reynaud-Gaubert, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 4, 2025
Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosisAntoine Gavoille, Mikail Nourredine, Fabien Rollot, et al.
Eclinicalmedicine|January 8, 2026
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO groupAnne Quinquenel, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Neurology|December 23, 2022
Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal InferenceAntoine Gavoille, Fabien Rollot, Romain Casey, et al.
Lancet (London, England)|October 14, 2023
Endovascular thrombectomy for acute ischaemic stroke with established large infarct: multicentre, open-label, randomised trialMartin Bendszus, Jens Fiehler, Fabien Subtil, et al.
The Lancet. Neurology|July 29, 2024
Endovascular thrombectomy for acute ischaemic stroke with established large infarct (TENSION): 12-month outcomes of a multicentre, open-label, randomised trialGötz Thomalla, Jens Fiehler, Fabien Subtil, et al.
Pageof 17

Showing results (151-160 of 165) with videos related to

Sort By:
Pageof 17
American Journal of Hematology|December 11, 2020
First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French studyMarie-Charlotte Laude, Laure Lebras, Pierre Sesques, et al.
Blood|November 9, 2020
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trialAnne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, et al.
The Lancet. Haematology|July 21, 2019
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trialAnne-Sophie Michallet, Marie-Sarah Dilhuydy, Fabien Subtil, et al.
JAMA Neurology|August 4, 2025
Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple SclerosisAntoine Gavoille, Fabien Rollot, Romain Casey, et al.
The European Respiratory Journal|March 26, 2026
Prognostic factors in interstitial lung disease-associated pulmonary hypertension: data from the HYPID cohort and the French Pulmonary Hypertension RegistryRémi Diesler, Ségolène Turquier, Martine Reynaud-Gaubert, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 4, 2025
Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosisAntoine Gavoille, Mikail Nourredine, Fabien Rollot, et al.
Eclinicalmedicine|January 8, 2026
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO groupAnne Quinquenel, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Neurology|December 23, 2022
Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal InferenceAntoine Gavoille, Fabien Rollot, Romain Casey, et al.
Lancet (London, England)|October 14, 2023
Endovascular thrombectomy for acute ischaemic stroke with established large infarct: multicentre, open-label, randomised trialMartin Bendszus, Jens Fiehler, Fabien Subtil, et al.
The Lancet. Neurology|July 29, 2024
Endovascular thrombectomy for acute ischaemic stroke with established large infarct (TENSION): 12-month outcomes of a multicentre, open-label, randomised trialGötz Thomalla, Jens Fiehler, Fabien Subtil, et al.
Pageof 17